- With Mayo Clinic psychiatrist
David Mrazek, M.D.
read biographyclose windowBiography of
David Mrazek, M.D.
David Mrazek, M.D.
Dr. David A. Mrazek is chair of the Department of Psychiatry and Psychology at Mayo Clinic, Rochester, Minn., and a professor of psychiatry at College of Medicine, Mayo Clinic. Dr. Mrazek has developed a federally funded psychiatric pharmacogenomics research program and implemented clinical psychiatric pharmacogenomics services at Mayo Clinic.
He has received numerous awards including the Award for Creativity in Psychiatric Education from the American College of Psychiatrists and the Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent Psychiatry from the American Psychiatric Association. He currently serves as chairman of the board of the American Board of Psychiatry and Neurology.
Dr. Mrazek has focused his current efforts on using pharmacogenomics testing to improve clinical care. One of his specific goals is to decrease the risks of taking psychiatric medications.
Latest entries
- Complexity of depression diagnosis makes treatment difficult
March 8, 2012
- Depression sometimes shifts to bipolar disorder
Jan. 21, 2012
- Antidepressant use soaring among Americans 12 and over
Dec. 7, 2011
- Transcranial magnetic stimulation offers hope treating depression
Oct. 19, 2011
- New antidepressant offers hope
Sept. 3, 2011
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Depression blog
-
July 22, 2011
Sorting out the evidence for antidepressants
By David Mrazek, M.D.
In the July 9 New York Times, Dr. Peter Kramer wrote a piece titled, "In Defense of Antidepressants". It seems ironic that such an article is needed, given the substantial evidence that antidepressants have helped millions of people. However, there continues to be a confusing, academic argument about some of the studies of antidepressants.
| Need more help? |
|
Dr. Kramer is a gifted psychiatrist. He achieved national recognition 18 years ago when he wrote the book "Listening to Prozac". He made his patients come to life for the reader. I read the book and was impressed by how many people he had helped to find their way forward by combining sensitive psychotherapy and appropriate use of one of the earliest serotonin reuptake inhibitors, Prozac.
While his recent article takes on a difficult topic, I was pleased that the paper published it. While some of the details are too esoteric for most readers to follow, the balance of evidence clearly demonstrates that antidepressants work. That's also the conclusion of the FDA and is the experience of many people who have recovered from a serious depression.
Of course, as has been discussed at great lengths on this blog, not all antidepressants work for everyone. Additionally, for some of you, the side effects can be intolerable. Despite millions of dollars of research, the process of finding the right antidepressant is still a difficult one.
While some new tools, such as pharmacogenomic testing, make this process somewhat more rational, it's clear that the search for a better antidepressant must continue and that research designed to identify which people will respond to which medication should have a high funding priority from the National Institute of Health.
One type of study that Dr. Kramer discusses is particularly interesting and rarely considered. These are "maintenance studies". In his article, Dr. Kramer refers to a large study of 4,410 patients who initially had a good response to an antidepressant. The study was designed to focus on the question of how long to continue treatment. The study also wanted to examine the possibility that some patients may respond to treatment as a consequence of other factors besides their medication.
In this study, after successful treatment, half of the patients were switched to a placebo and the remainder continued to receive their active antidepressant. The participants didn't know if they were still getting their antidepressant or had been switched to a sugar pill. In many ways, this is a tough study to volunteer to be in. However, the results were clear. About 70 percent of those who were switched to the placebo relapsed, while most who remained on their medication didn't relapse.
This finding strongly suggests that simply believing that you're taking your antidepressant is not sufficient to maintain a good response. This result makes good sense and supports the importance of staying on a medication that's working.
A link to Dr. Kramer's article can be found in the Resources tab above.
Please share your thoughts.
31 comments posted
Share on:
31 comments posted